Effect of Terlipressin on the Incidence of Early Postoperative Acute Kidney Injury in Liver Transplantation Patients

Beijing Tsinghua Chang Gung Hospital

Status and phase: Enrolling; Phase 4

Conditions: Liver Transplant; Complications; Acute Kidney Injury

Treatments: Drug: Terlipressin; Drug: normal saline

Study type: Interventional

Funder types: Other

Identifiers

NCT06108362

23344-4-02

Details and patient eligibility

About

The goal of this clinical trial is to evaluate the effect of intraoperative terlipressin on the incidence of early postoperative acute kidney injury in deceased doner liver transplantation. Patients were randomly divided into experimental group and control group by numerical randomization table. The experimental group was injected with terlipressin perioperative and the control group was injected with placebo

Full description

acute kidney injury is a relatively common complication in patients with liver transplantation. Most centers have established prediction models for acute kidney injury after liver transplantation, but the incidence cannot be reduced through perioperative anesthesia management. As an vasopressin receptor agonist, terlipressin can increase blood pressure and improve kidney perfusion at the same time, and perioperative application may reduce the incidence of postoperative acute kidney injury

Enrollment: 104 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1. Patients who plan to undergo liver transplantation in our hospital 2) Patients or family members sign informed consent

Exclusion criteria

• Patients <18 years old;② Patients undergoing autologous liver transplantation or combined transplantation;③ Patients with lower extremity artery stenosis;(4) Patients with severe heart disease、lung disease、kidney disease;⑤ Patients with severe lung disease;⑥ Patients who used renal replacement therapy before surgery;⑦ the depth of one kidney from the body surface is greater than 4cm;⑧ Patients treated with terlipressin within 2 weeks before surgery⑨ Patients allergic to terlipressin.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

104 participants in 2 patient groups, including a placebo group

experimental group

Experimental group

Description:

Continuous terlipressin infusion，Use a syringe to dilute to 50ml Infusion speed is 2ug/kg\*h, From the beginning to the end of the surgery.

Treatment:

Drug: Terlipressin

control group

Placebo Comparator group

Description:

Continuous normal saline infusion，Use a syringe to draw 50ml Infusion speed is 4ml/h, From the beginning to the end of the surgery.

Treatment:

Drug: normal saline